Cerebral degeneration

This completed Phase 2 trial tested an oral drug called LY3372689 in 327 people with early symptomatic Alzheimer's disease. The goal was to see if the drug could safely slow down declines in thinking and daily living skills compared to a placebo. The study focused on participants…

This early-stage trial tested a drug called NIO752 in 59 people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and balance. The drug was given as a spinal injection to see if it is safe and how the body processes it. The main goal was to ch…

This early-phase study tests two new imaging drugs, [18F]ABBV-964i and [18F]ABBV-965i, designed to light up tau protein buildup in the brain during a PET scan. Tau buildup is linked to Progressive Supranuclear Palsy (PSP), a rare movement and thinking disorder. The trial includes…

This study tested whether a single infusion of zoledronic acid (Reclast) can prevent fractures in men and women aged 60 and older with Parkinson's disease or related conditions. Over 2,700 participants were randomly assigned to receive either the drug or a placebo, and were follo…

This study tested whether lithium, a drug used for mood disorders, can prevent Alzheimer's dementia in older adults with mild cognitive impairment (MCI). 83 participants took either lithium or a placebo for a period, and researchers measured memory, thinking skills, and brain cha…

This study tested whether a daily supplement called ETAS®, made from asparagus, could improve memory, mood, and reduce inflammation in healthy adults aged 60-80 who had mild memory concerns. 45 participants took either a low or high dose of ETAS® or a placebo for 12 weeks. Resear…

This study tests whether wearable sensors and caregiver questionnaires can capture the behavioral signs of apathy in people with dementia during daily life. Patients with Alzheimer's or frontotemporal dementia and their caregivers wear a sensor bracelet for 28 days, while caregiv…

This study looked at whether opioid use disorder and non-fatal overdoses cause a harmful protein called tau to build up in the brain. Researchers used special PET/CT scans on 12 adults, including those with opioid use disorder and healthy volunteers. The goal was to understand lo…

This study examined 186 people with Alzheimer's, Lewy body, frontotemporal, or corticobasal dementia, plus healthy controls, to see if subtle physical signs (like coordination or reflexes) differ between dementia types. Participants had simple exams and cognitive tests. The goal …

This completed observational study enrolled 1,141 participants with mild cognitive impairment or Alzheimer's disease. Researchers tracked changes in memory tests, brain scans, and other biomarkers over time. The goal was to improve how future clinical trials measure the disease, …

This study interviewed 26 adults who either have behavioral variant frontotemporal dementia (bvFTD) or carry a gene that puts them at risk. The goal was to learn how the condition affects daily life, emotions, and coping. No treatment or medication was tested—just listening and g…

This study surveyed 219 family caregivers of people with dementia to explore how swallowing problems (dysphagia) affect their burden and needs. Caregivers completed a one-time online questionnaire about their experiences, stress, and knowledge. The goal is to better understand an…

This study tested a special PET scan tracer (F-18 AV 1451) to see how much tau protein builds up in the brains of 81 people with primary progressive aphasia or frontotemporal dementia. Researchers compared these scans to those of healthy controls to find unique patterns for each …